Give me high yield conceptual MCQS on anti diuretics pharmacology
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
I now have rich, textbook-sourced content. Let me compile a comprehensive set of high-yield MCQs.
High-Yield MCQs: Antidiuretics Pharmacology
Q1. Receptor Selectivity of Desmopressin
A 28-year-old man with central diabetes insipidus is started on desmopressin. Compared to native vasopressin (AVP), which of the following best describes desmopressin's receptor selectivity?
A. Equal V1 and V2 agonism
B. Selective V1a agonist with minimal V2 activity
C. Selective V2 agonist with minimal V1 (pressor) activity
D. Pure V1b agonist acting on the pituitary
E. Non-selective V1/V2 agonist with enhanced V1 potency
Answer & Explanation
Answer: C
Desmopressin (DDAVP, 1-desamino-8-D-arginine vasopressin) has an antidiuretic-to-pressor ratio 4000 times greater than native vasopressin. Structural modifications at position 1 (desaminocysteine) and position 8 (D-arginine instead of L-arginine) eliminate most V1-mediated vasoconstriction while preserving V2-mediated antidiuresis. This makes it safe to use even in patients with coronary artery disease (unlike vasopressin, which must be used cautiously due to vasoconstriction).
Source: Katzung's Basic and Clinical Pharmacology, 16e
Q2. Mechanism of Action at the Collecting Duct
A medical student is asked about the intracellular signaling downstream of V2 receptor activation. Which of the following correctly describes the sequence?
A. V2 → Gq → phospholipase C → IP3 → intracellular Ca²⁺ → aquaporin-2 insertion
B. V2 → Gs → adenylyl cyclase → cAMP → PKA → aquaporin-2 trafficking to apical membrane
C. V2 → Gi → inhibition of adenylyl cyclase → decreased cAMP → aquaporin-2 insertion
D. V2 → Gq → DAG → PKC → aquaporin-3 upregulation at apical membrane
E. V2 → Gs → phospholipase C → PKA → aquaporin-1 insertion
Answer & Explanation
Answer: B
V2 receptors on principal cells of the collecting duct couple to Gs → adenylyl cyclase → ↑cAMP → PKA activation. PKA phosphorylates Ser256 on aquaporin-2, shifting the trafficking balance toward the apical membrane, increasing water permeability. Aquaporin-3 and AQP-4 serve as the basolateral exit channels. Note: V1 receptors (vascular) couple to Gq → phospholipase C → IP3/DAG → vasoconstriction.
Source: Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung's 16e
Q3. Drug That Enhances the Antidiuretic Response
A 45-year-old woman with partial central diabetes insipidus is taking indomethacin for arthritis. She notices a significant decrease in her urine output. Which mechanism explains this drug interaction?
A. Indomethacin directly activates V2 receptors
B. NSAIDs inhibit prostaglandin synthesis, removing PG-mediated attenuation of vasopressin's antidiuretic effect
C. Indomethacin increases vasopressin release from the posterior pituitary
D. NSAIDs block aquaporin-2 degradation at the collecting duct
E. Indomethacin inhibits renal V1 receptor-mediated water loss
Answer & Explanation
Answer: B
Prostaglandins (PGs) normally attenuate the antidiuretic response to vasopressin. NSAIDs (especially indomethacin) inhibit PG synthesis, which removes this inhibitory brake, thereby potentiating vasopressin's antidiuretic effect. This is exploited clinically in treating partial nephrogenic DI. Similarly, carbamazepine and chlorpropamide also enhance antidiuretic effects (by unknown mechanisms).
Source: Goodman & Gilman's 13e
Q4. Drug That Inhibits the Antidiuretic Response
A psychiatrist starts a patient on lithium carbonate for bipolar disorder. Which of the following best explains lithium's renal side effect of causing nephrogenic diabetes insipidus?
A. Lithium blocks V2 receptors at the collecting duct membrane
B. Lithium reduces V2 receptor-mediated stimulation of adenylyl cyclase and increases PTH (a partial vasopressin antagonist)
C. Lithium irreversibly inactivates aquaporin-2 channels
D. Lithium stimulates V1 receptors causing vasoconstriction that reduces medullary blood flow
E. Lithium increases PG synthesis, which enhances V2 receptor downregulation
Answer & Explanation
Answer: B
Lithium appears to reduce V2 receptor-mediated stimulation of adenylyl cyclase, thereby decreasing cAMP production and aquaporin-2 insertion. Additionally, lithium increases plasma PTH, which acts as a partial vasopressin antagonist. The result is acquired nephrogenic DI - the kidneys produce AVP normally but are resistant to its action. Demeclocycline (a tetracycline) also causes nephrogenic DI by decreasing cAMP accumulation - this is intentionally exploited to treat SIADH.
Source: Goodman & Gilman's 13e; Goldman-Cecil Medicine
Q5. Half-Life and Route Comparison
Which of the following statements about the pharmacokinetics of vasopressin vs. desmopressin is CORRECT?
A. Both have a half-life of approximately 15 minutes when given IV
B. Native vasopressin has a half-life of ~15 minutes; desmopressin has a half-life of ~1.5-2.5 hours
C. Oral desmopressin has 30-40% bioavailability
D. Desmopressin is only available for intranasal and IV administration
E. Vasopressin is resistant to hepatic and renal metabolism
Answer & Explanation
Answer: B
- Vasopressin t½: ~15 minutes (metabolized by renal and hepatic reduction of disulfide bond and peptide cleavage)
- Desmopressin t½: 1.5-2.5 hours
- Nasal desmopressin bioavailability: 3-4%; oral bioavailability: <1% (enteral absorption is also decreased ~50% when taken with meals)
- Desmopressin is available IV, SC, intranasal, and oral
Source: Katzung's Basic and Clinical Pharmacology, 16e
Q6. Conivaptan vs. Tolvaptan - Clinical Distinction
A patient with dilutional hyponatremia (Na⁺ 118 mEq/L) due to SIADH is admitted to the ICU. Which of the following best distinguishes conivaptan from tolvaptan?
A. Conivaptan is oral; tolvaptan is IV only
B. Conivaptan selectively blocks V2; tolvaptan blocks both V1a and V2
C. Conivaptan is IV and non-selective (V1a/V2); tolvaptan is oral and selective V2
D. Tolvaptan has no hepatotoxicity risk; conivaptan is limited to 30 days
E. Both agents are approved for nephrogenic diabetes insipidus
Answer & Explanation
Answer: C
| Feature | Conivaptan | Tolvaptan |
|---|---|---|
| Route | IV only | Oral |
| Selectivity | V1a + V2 (non-selective) | V2 selective (30× higher affinity for V2 than V1) |
| Indication | Euvolemic/hypervolemic hyponatremia | Same + ADPKD |
| Key risk | - | Hepatotoxicity (limit to 30 days; monitor LFTs) |
Tolvaptan duration is limited to 30 days due to risk of life-threatening liver failure. Neither agent is used for DI treatment; they are used for hyponatremia and heart failure.
Source: Katzung's Basic and Clinical Pharmacology, 16e; Harrison's Principles of Internal Medicine 22e
Q7. DDAVP in Coagulopathy - Mechanism
A uremic patient requires an invasive procedure. Desmopressin is administered. Which mechanism best explains its hemostatic effect?
A. V1a receptor activation on platelets directly promotes aggregation
B. V2-like extrarenal receptors trigger release of coagulation factor VIII and von Willebrand factor from endothelial cells
C. Desmopressin inhibits fibrinolysis by blocking tissue plasminogen activator
D. Desmopressin stimulates thrombopoietin release, increasing platelet count
E. Desmopressin activates the extrinsic coagulation pathway via tissue factor upregulation
Answer & Explanation
Answer: B
Extrarenal V2-like receptors on vascular endothelium regulate the release of factor VIII and von Willebrand factor (vWF), enhancing platelet aggregation. This is why desmopressin is used clinically for:
- Uremic bleeding
- Mild hemophilia A (transiently raises factor VIII)
- Type 1 von Willebrand disease
Note: Desmopressin is NOT useful in hemophilia B (factor IX deficiency) or type 3 VWD (no stored vWF).
Source: Katzung's Basic and Clinical Pharmacology, 16e; Barash Clinical Anesthesia 9e
Q8. Central vs. Nephrogenic DI - Diagnostic & Treatment
A 35-year-old man presents with polyuria (8 L/day) and polydipsia. After water deprivation, urine osmolality fails to rise above 200 mOsm/kg. Administration of exogenous desmopressin raises urine osmolality to >700 mOsm/kg. What is the diagnosis and treatment of choice?
A. Nephrogenic DI; hydrochlorothiazide + amiloride
B. Central (pituitary) DI; desmopressin
C. Primary polydipsia; water restriction only
D. Nephrogenic DI; demeclocycline
E. SIADH; fluid restriction
Answer & Explanation
Answer: B
The key finding is response to exogenous desmopressin - urine osmolality rises appropriately, indicating the kidney is capable of responding to ADH. This points to central (pituitary/hypothalamic) DI - lack of AVP production/secretion.
- Central DI: responds to DDAVP → treat with desmopressin (drug of choice)
- Nephrogenic DI: does NOT respond to DDAVP → treat with thiazide diuretics + amiloride + NSAIDs + low-sodium diet
Central DI causes include tumors, head trauma, neurosurgical procedures, and congenital conditions affecting the hypothalamic/posterior pituitary axis.
Source: Katzung's 16e; Comprehensive Clinical Nephrology 7e
Q9. Tolvaptan's Primary Warning
A 52-year-old man is started on tolvaptan for SIADH-related hyponatremia. Which monitoring parameter is MOST important?
A. Serum potassium (risk of hyperkalemia)
B. Liver function tests (ALT, AST, bilirubin) - risk of hepatotoxicity
C. Serum creatinine - risk of acute kidney injury
D. CBC - risk of agranulocytosis
E. Serum phosphate - risk of hypophosphatemia
Answer & Explanation
Answer: B
Tolvaptan carries a black box warning for hepatotoxicity, including life-threatening liver failure. Treatment is limited to 30 days and requires regular monitoring of ALT, AST, and bilirubin. For this reason, tolvaptan is contraindicated in patients with liver disease. Conivaptan (IV) does not carry this same restriction.
Source: Katzung's Basic and Clinical Pharmacology, 16e
Q10. Demeclocycline - Clinical Use in SIADH
Why is demeclocycline used in SIADH despite being a tetracycline antibiotic?
A. It blocks hypothalamic AVP secretion centrally
B. It enhances renal prostaglandin synthesis, counteracting V2 stimulation
C. It decreases cAMP accumulation in collecting duct cells, creating nephrogenic DI that promotes free water excretion
D. It competitively blocks V2 receptors at the collecting duct
E. It activates solute cotransporters in the loop of Henle, increasing urinary osmolality
Answer & Explanation
Answer: C
Demeclocycline attenuates antidiuretic effects of vasopressin by decreasing cAMP accumulation and action in collecting duct cells, effectively inducing an iatrogenic nephrogenic DI. This promotes free water excretion, raising serum sodium in SIADH. However, it has largely been replaced by vaptans (tolvaptan, conivaptan) which are more targeted. Demeclocycline is nephrotoxic and requires careful use in patients with liver disease.
Source: Goodman & Gilman's 13e; Goldman-Cecil Medicine
Q11. Aquaporin Distribution - Water Channel Specificity
Which aquaporin is the primary vasopressin-regulated water channel in the kidney?
A. Aquaporin-1 (AQP1) - proximal tubule and descending thin limb
B. Aquaporin-2 (AQP2) - apical membrane of collecting duct principal cells
C. Aquaporin-3 (AQP3) - apical membrane of collecting duct
D. Aquaporin-4 (AQP4) - apical membrane of proximal tubule
E. Aquaporin-7 (AQP7) - principal cell apical membrane
Answer & Explanation
Answer: B
- AQP1: proximal tubule + descending thin limb (DTL) - constitutive, NOT regulated by vasopressin
- AQP2: principal cells of connecting tubule and collecting duct - the key vasopressin-regulated channel (apical membrane)
- AQP3 and AQP4: basolateral membranes of collecting duct - provide exit for reabsorbed water
- AQP7: apical brush border of straight proximal tubule
V2 activation → PKA phosphorylates AQP2 → trafficking to apical membrane → water reabsorption.
Source: Goodman & Gilman's 13e (Figure 29-13 description)
Q12. Vasopressin in Vasodilatory Shock
In a patient in refractory septic shock not responding to norepinephrine alone, vasopressin (not desmopressin) is added. Which receptor mediates its vasopressor effect, and what is the downstream signaling?
A. V2 → Gs → cAMP → smooth muscle relaxation
B. V1a → Gq → phospholipase C → IP3/DAG → intracellular Ca²⁺ → vasoconstriction
C. V1b → Gi → decreased cAMP → ACTH release
D. V2 → Gq → phospholipase C → vasoconstriction
E. V1a → Gs → adenylyl cyclase → PKA → vasoconstriction
Answer & Explanation
Answer: B
V1 receptors (V1a subtype) are on vascular smooth muscle cells and couple to Gq (not Gi or Gs). Gq activates phospholipase C, generating IP3 (raises intracellular Ca²⁺) and DAG (activates PKC), causing vasoconstriction. This is why native vasopressin (not desmopressin) is used in shock - it has significant V1a pressor activity. Desmopressin's antidiuretic:pressor ratio is 4000× higher than vasopressin, so it has negligible V1a activity.
Source: Katzung's 16e; Goodman & Gilman's 13e
Quick Summary Table
| Drug | Receptor | Route | Key Use | Key Toxicity |
|---|---|---|---|---|
| Vasopressin | V1a + V2 | IV/IM | Shock, variceal bleed, DI | Vasoconstriction, ischemia |
| Desmopressin | V2 >> V1 | IV/SC/intranasal/oral | Central DI, enuresis, hemophilia A, vWD | Hyponatremia (water intoxication) |
| Tolvaptan | V2 antagonist | Oral | SIADH, heart failure, ADPKD | Hepatotoxicity (30-day limit) |
| Conivaptan | V1a + V2 antagonist | IV only | SIADH, euvolemic/hypervolemic hyponatremia | Infusion site reactions |
| Demeclocycline | Blocks cAMP in collecting duct | Oral | SIADH (second-line) | Nephrotoxicity, photosensitivity |
| Lithium | Reduces V2-AC coupling | Oral | Bipolar (side effect = NDI) | Nephrogenic DI, neurotoxicity |
Sources: Katzung's Basic & Clinical Pharmacology 16e; Goodman & Gilman's Pharmacological Basis of Therapeutics 13e; Harrison's Principles of Internal Medicine 22e; Comprehensive Clinical Nephrology 7e; Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.